Literature DB >> 1900225

Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.

D C Gulba1, M Barthels, M Westhoff-Bleck, S Jost, W Rafflenbeul, W G Daniel, H Hecker, P R Lichtlen.   

Abstract

BACKGROUND: It has been suggested that thrombolysis in a feedback reaction may generate pro-coagulant activities. METHODS AND
RESULTS: Fifty-five patients were treated with urokinase-preactivated prourokinase (n = 35) or tissue-type plasminogen activator (n = 20) for acute myocardial infarction and underwent coronary angiography at 90 minutes and at 24-36 hours into thrombolysis, and fibrinogen (Ratnoff-Menzie), D-dimer (ELISA) and thrombin-antithrombin III complex levels (ELISA) were measured. Primary patency was achieved in 39 patients (70.9%), 13 of whom (33.3%) suffered early reocclusion. Nonsignificant decreases in fibrinogen levels were observed while D-dimer levels increased +3,008 +/- 4,047 micrograms/l (p less than 0.01), differences not being significant in respect to the thrombolytic agents or to the clinical course. In contrast, while thrombin-antithrombin III complex levels decreased -4.4 +/- 13.0 micrograms/l in patients with persistent patency, they increased +7.5 +/- 13.6 micrograms/l in case of nonsuccessful thrombolysis (p less than 0.02) and +11.9 +/- 23.8 micrograms/l in case of early reocclusion (p less than 0.001). For patients with thrombin-antithrombin III complex levels greater than 6 ng/l 120 minutes into thrombolysis, the unfavorable clinical course was predicted with 96.2% sensitivity and 93.1% specificity.
CONCLUSION: Generation of thrombin, occurring during thrombolysis, is a major determinant for the success of therapy and thrombin-antithrombin III levels may serve as predictors for the short-term prognosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900225     DOI: 10.1161/01.cir.83.3.937

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Guidelines for the Management of Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

Review 3.  Platelet activation in acute myocardial infarction and the rationale for combination therapy.

Authors:  I Conde-Pozzi; N Kleiman
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

4.  Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Authors:  Ulf Bertram; Martin Moser; Karlheinz Peter; Helmut F Kuecherer; Raffi Bekeredjian; Andreas Straub; Thomas K Nordt; Christoph Bode; Johannes Ruef
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

5.  Current status of thrombolytic therapy in acute myocardial infarction.

Authors:  B Stein; R Roberts
Journal:  Tex Heart Inst J       Date:  1991

6.  The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

7.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 8.  Hirudin and excess bleeding. Implications for future use.

Authors:  U Zeymer; K L Neuhaus
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 9.  Vessel wall-related risk factors in acute vascular events.

Authors:  L Badimon; J J Badimon; M Cohen; J H Chesebro; V Fuster
Journal:  Drugs       Date:  1991       Impact factor: 9.546

10.  Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.

Authors:  O D Pedersen; J Gram; J Jespersen
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.